Horizon Discovery Share Discussion Threads

[thomasthetank1] 26/4/2016 12:40

Read Panmure Gordon & Co's note on HORIZON DISCOVERY GROUP, out this morning, by visiting hxxps://www.research-tree.com/company/GB00BK8FL363
"Today’s prelims follow the mid-January trading update and, therefore, sales performance of £20.2m (PGe £20.1m) comes as no surprise. The group reports an adjusted (before net exceptional items benefit of £0.4m) pre-tax loss of £10.9m vs our estimate PGe adj loss £10.0m. After the net impact of exceptionals, finance costs and tax benefit the reported loss per share of 11.2p comes in line with our 11.4p loss estimate. There’s minimal additional information on outlook/current trading within today’s statement, so we’ll be looking for more information at this morning’s analyst meeting...."

[deltrotter] 26/4/2016 11:39

The Gaffer video just out:

[deltrotter] 26/4/2016 08:55

Cracking British company this IMO. Great management team.

[small crow] 26/4/2016 08:53

Results look excellent.

[mamcw] 21/4/2016 07:44

Two new advisers, two new buy notes - nothing changes in the City. However, I still see no reason to doubt that this company will turn out to be a real winner

[deltrotter] 20/4/2016 20:09

" Focussing on the small cap market, City broker Numis Securities began its coverage of Horizon Discovery Plc (LON:HZD) with a ‘buy’ recommendation and a 252p price target that implies some 50% to the current price of 171p.

Numis analyst Paul Cuddon, in a note, said he expected the expert-gene editor’s to double sales by 2018 and his write up focussed on the group’s “key strategic position in a fast-growing pharmaceutical market”."

[jugu] 20/4/2016 13:28

This is down to change in advisor.

[andrewbaker] 20/4/2016 11:45

Maybe the start of something big, lol. :)

[phowdo] 20/4/2016 11:35

broken the high of 172.80 from last September.
Long way to go if this is to follow a similar path to ABCam

[nurdin] 20/4/2016 11:15

Going up with intent now ! :o)

[jugu] 19/4/2016 10:51

Spread has narrowed for first time, should encourage some volume.

[jugu] 18/4/2016 10:38

Looks good expecting good results and some insti buying with assistance from new brokers, RBC research note must have substance as would look bad if results/outlook don't look so positive.

[mamcw] 18/4/2016 10:23

The change of broker explains the large RBC research note published on 4 April. Expecting something equally weighty from Numis before too long.

[jugu] 14/4/2016 19:02

Some news today:
hxxps://www.horizondiscovery.com/about-us/news/agena-bioscience-and-horizon-discovery-to-launch-iplex-reference-standards-for-the-massarray-system

[deltrotter] 04/4/2016 15:45

Equities researchers at RBC Capital initiated coverage on shares of Horizon Discovery Group PLC (LON:HZD) in a research note issued on Monday, ARN reports. The brokerage set an “outperform221; rating and a GBX 210 ($2.99) price target on the stock. RBC Capital’s price objective would indicate a potential upside of 36.81% from the stock’s previous close.

[small crow] 30/3/2016 07:41

hxxps://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&partnerref=Email1&utm_campaign=NEWSLETTER_TS_WEBINAR-LIVE_2016&utm_source=hs_email&utm_medium=email&utm_content=27676405&;_hsenc=p2ANqtz--pVGdqhSbI_Ap2FC2IOWuBX_vqF-48qYqczOfcLBYzBmwDNEU6HyXRoZU7nynktzETlyZ6nkueBRuNu_fnE1JyJRq-Rg&_hsmi=27676405&eventid=1157449&sessionid=1&key=D49F41BCDBB6D2FAAC3643F5ADECF94D&regTag=&;sourcepage=register

Webinar: Title: Bioproduction: Advances in Cell Line EngineeringSummary

Bioproduction involves the growth and manipulation of large quantities of cells under tightly controlled conditions mandated by good manufacturing practices (GMP), while maintaining quality, reproducibility, and cost. Innovative technologies and strategies are being employed to optimize scale-up to high-throughput production. The Scientist brings together a panel of experts to discuss strategies and workflows for screening and optimizing cell lines for bioproduction. Attendees can interact with the panel during the live webinar by asking questions and sharing their experiences in cell line engineering.

Topics to be covered:

Genome-editing approaches for bioproduction
Analysis and leverage of screening and omics data to guide cell line engineering for biotherapeutic development

Speakers

Dr. Jamie Freeman
Product Manager, Bioproduction
Horizon Discovery

Dr. Nathan Lewis
Assistant Professor, Department of Pediatrics
University of California, San Diego

[mirandaj] 24/3/2016 12:48

Horizon Discovery form joint venture, 'Avvinity Therapeutics' with Centauri Therapeutics

[small crow] 15/3/2016 10:20

My buy showing as a sell (at 155) this am.

[mr dexy] 14/3/2016 15:42

Professor Andrew Baker?

[andrewbaker] 14/3/2016 15:33

The general economic malaise is holding back HZD, but that just means there is plenty of opportunity to buy/add at low prices. I'm long, considering adding, and staying long for what will become a very profitable ride north, IMHO.

The technology here of gene editing is a massive growth area, and Horizon is right in there at the centre of things.

[cumbrian2] 10/3/2016 16:00

The only licking I have been doing for last year has been my wounds! Still, anticipating a much better year and see this as a long term hold and remains approx 10% of my portfolio.

[pjj71] 10/3/2016 14:35

Good watch - makes you want to lip your lips at the opportunity ahead.

[kestelmill] 09/3/2016 17:51

thank you for posting the presentation. I watched the whole thing and I thought he explained very simply and clearly; even I could understand it. Very interesting insights.
-AAV has advantages over CRISPr and only Horizon can do AAV
-R&D people would rather buy ready-made edited cells than do it themselves (quicker, cheaper)
-Vending machine model
-Haplogen acquisition gave high throughput system for gene editing
-Market has been flooded with shares due to acquisitions which may have driven down share price